Barclays PLC Has $2.88 Million Stock Position in InMode Ltd. (NASDAQ:INMD)

Barclays PLC boosted its stake in shares of InMode Ltd. (NASDAQ:INMD) by 113.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 169,630 shares of the healthcare company’s stock after buying an additional 90,173 shares during the period. Barclays PLC’s holdings in InMode were worth $2,876,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Asset Dedication LLC purchased a new position in InMode during the 2nd quarter worth approximately $33,000. nVerses Capital LLC acquired a new stake in shares of InMode in the second quarter worth $42,000. Nisa Investment Advisors LLC boosted its position in shares of InMode by 314.7% in the third quarter. Nisa Investment Advisors LLC now owns 3,550 shares of the healthcare company’s stock worth $60,000 after buying an additional 2,694 shares during the period. Quarry LP grew its holdings in shares of InMode by 154.3% during the third quarter. Quarry LP now owns 3,781 shares of the healthcare company’s stock valued at $64,000 after buying an additional 2,294 shares in the last quarter. Finally, National Bank of Canada FI raised its position in InMode by 40.7% during the second quarter. National Bank of Canada FI now owns 9,406 shares of the healthcare company’s stock valued at $168,000 after buying an additional 2,720 shares during the period. 68.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

INMD has been the subject of several research reports. Needham & Company LLC restated a “hold” rating on shares of InMode in a report on Thursday, October 31st. Barclays decreased their target price on shares of InMode from $29.00 to $27.00 and set an “overweight” rating for the company in a research note on Monday, October 14th. Finally, BTIG Research began coverage on shares of InMode in a research note on Thursday, October 17th. They issued a “buy” rating and a $25.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $22.60.

InMode Trading Up 0.6 %

InMode stock opened at $17.06 on Wednesday. InMode Ltd. has a 1-year low of $14.87 and a 1-year high of $26.80. The firm’s fifty day simple moving average is $18.28 and its 200-day simple moving average is $17.42. The company has a market capitalization of $1.43 billion, a P/E ratio of 9.22 and a beta of 2.07.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.